FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1905645497> ?p ?o ?g. }

• W1905645497 startingPage "2910" @default.
• W1905645497 abstract "Background The effect of QGE031, a high-affinity humanized anti-IgE antibody, was evaluated versus omalizumab (OMA) and placebo in a bronchial allergen challenge model.Methods In this phase IIa, exploratory, parallel group, double-blind, placebo controlled study, 37 subjects with mild atopic asthma were randomized to three s.c. doses (240mg; N=8, 72mg; N=8 and 24mg; N=8) of QGE031 every two weeks, OMA (N=6; dosed as per dosing table) or placebo (N=7). The study was powered for a 0.05 significance level. Outcome measures were change from baseline in the concentration of inhaled allergen leading to a 15% decline in FEV1 (PC15FEV1) at 12 weeks, pharmacodynamics, safety and tolerability.Results At week 12, the change in PC15FEV1 was ∼ 3 fold higher with 72mg and 240mg QGE031 compared to OMA (Table). The change in PC15FEV1 was dose-dependent against both placebo and OMA, with 24mg QGE031 showing a smaller effect whilst 72mg and 240mg showed a similar effect size. QGE031 elicited dose and time-dependent suppression of free IgE, basophil Fc∈RI, surface IgE expression and skin prick test responses. QGE031 was well tolerated at all dose levels.View this table:Table: PC15FEV1 for QGE031 versus placebo and omalizumab at 12 weeksConclusion QGE031 240 and 72mg demonstrated greater improvement in bronchial provocation testing compared to placebo, and both doses showed a trend for improvement compared with OMA." @default.
• W1905645497 created "2016-06-24" @default.
• W1905645497 creator A5005190096 @default.
• W1905645497 creator A5006247977 @default.
• W1905645497 creator A5008276450 @default.
• W1905645497 creator A5018374796 @default.
• W1905645497 creator A5020298279 @default.
• W1905645497 creator A5024843726 @default.
• W1905645497 creator A5026242254 @default.
• W1905645497 creator A5029497606 @default.
• W1905645497 creator A5035835345 @default.
• W1905645497 creator A5041071402 @default.
• W1905645497 creator A5047495963 @default.
• W1905645497 creator A5058619951 @default.
• W1905645497 creator A5063934056 @default.
• W1905645497 creator A5064414623 @default.
• W1905645497 creator A5066222424 @default.
• W1905645497 creator A5066255013 @default.
• W1905645497 creator A5068301886 @default.
• W1905645497 creator A5068367175 @default.
• W1905645497 creator A5073165570 @default.
• W1905645497 creator A5073967383 @default.
• W1905645497 creator A5076937946 @default.
• W1905645497 creator A5080705201 @default.
• W1905645497 creator A5085602161 @default.
• W1905645497 creator A5087221887 @default.
• W1905645497 creator A5087705837 @default.
• W1905645497 date "2014-09-01" @default.
• W1905645497 modified "2023-10-03" @default.
• W1905645497 title "Late-breaking abstract: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response" @default.
• W1905645497 hasPublicationYear "2014" @default.
• W1905645497 type Work @default.
• W1905645497 sameAs 1905645497 @default.
• W1905645497 citedByCount "0" @default.
• W1905645497 crossrefType "journal-article" @default.
• W1905645497 hasAuthorship W1905645497A5005190096 @default.
• W1905645497 hasAuthorship W1905645497A5006247977 @default.
• W1905645497 hasAuthorship W1905645497A5008276450 @default.
• W1905645497 hasAuthorship W1905645497A5018374796 @default.
• W1905645497 hasAuthorship W1905645497A5020298279 @default.
• W1905645497 hasAuthorship W1905645497A5024843726 @default.
• W1905645497 hasAuthorship W1905645497A5026242254 @default.
• W1905645497 hasAuthorship W1905645497A5029497606 @default.
• W1905645497 hasAuthorship W1905645497A5035835345 @default.
• W1905645497 hasAuthorship W1905645497A5041071402 @default.
• W1905645497 hasAuthorship W1905645497A5047495963 @default.
• W1905645497 hasAuthorship W1905645497A5058619951 @default.
• W1905645497 hasAuthorship W1905645497A5063934056 @default.
• W1905645497 hasAuthorship W1905645497A5064414623 @default.
• W1905645497 hasAuthorship W1905645497A5066222424 @default.
• W1905645497 hasAuthorship W1905645497A5066255013 @default.
• W1905645497 hasAuthorship W1905645497A5068301886 @default.
• W1905645497 hasAuthorship W1905645497A5068367175 @default.
• W1905645497 hasAuthorship W1905645497A5073165570 @default.
• W1905645497 hasAuthorship W1905645497A5073967383 @default.
• W1905645497 hasAuthorship W1905645497A5076937946 @default.
• W1905645497 hasAuthorship W1905645497A5080705201 @default.
• W1905645497 hasAuthorship W1905645497A5085602161 @default.
• W1905645497 hasAuthorship W1905645497A5087221887 @default.
• W1905645497 hasAuthorship W1905645497A5087705837 @default.
• W1905645497 hasConcept C110586980 @default.
• W1905645497 hasConcept C126322002 @default.
• W1905645497 hasConcept C141105273 @default.
• W1905645497 hasConcept C142724271 @default.
• W1905645497 hasConcept C159654299 @default.
• W1905645497 hasConcept C197934379 @default.
• W1905645497 hasConcept C203014093 @default.
• W1905645497 hasConcept C204787440 @default.
• W1905645497 hasConcept C207480886 @default.
• W1905645497 hasConcept C27081682 @default.
• W1905645497 hasConcept C2776042228 @default.
• W1905645497 hasConcept C2778375690 @default.
• W1905645497 hasConcept C2778564945 @default.
• W1905645497 hasConcept C2780510475 @default.
• W1905645497 hasConcept C71924100 @default.
• W1905645497 hasConcept C98274493 @default.
• W1905645497 hasConceptScore W1905645497C110586980 @default.
• W1905645497 hasConceptScore W1905645497C126322002 @default.
• W1905645497 hasConceptScore W1905645497C141105273 @default.
• W1905645497 hasConceptScore W1905645497C142724271 @default.
• W1905645497 hasConceptScore W1905645497C159654299 @default.
• W1905645497 hasConceptScore W1905645497C197934379 @default.
• W1905645497 hasConceptScore W1905645497C203014093 @default.
• W1905645497 hasConceptScore W1905645497C204787440 @default.
• W1905645497 hasConceptScore W1905645497C207480886 @default.
• W1905645497 hasConceptScore W1905645497C27081682 @default.
• W1905645497 hasConceptScore W1905645497C2776042228 @default.
• W1905645497 hasConceptScore W1905645497C2778375690 @default.
• W1905645497 hasConceptScore W1905645497C2778564945 @default.
• W1905645497 hasConceptScore W1905645497C2780510475 @default.
• W1905645497 hasConceptScore W1905645497C71924100 @default.
• W1905645497 hasConceptScore W1905645497C98274493 @default.
• W1905645497 hasLocation W19056454971 @default.
• W1905645497 hasOpenAccess W1905645497 @default.
• W1905645497 hasPrimaryLocation W19056454971 @default.
• W1905645497 hasRelatedWork W1739399004 @default.
• W1905645497 hasRelatedWork W1744956883 @default.
• W1905645497 hasRelatedWork W1890804524 @default.
• W1905645497 hasRelatedWork W1922961350 @default.

• next